<html>
<head>
<title>转需！园区企业提供晚期或复发性非小细胞肺癌患者的免费治疗机会</title>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=1.0,user-scalable=0,viewport-fit=cover">
<style>
*{margin:0;padding:0;max-width:100%;box-sizing:border-box;}html{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;line-height:1.6}img{z-index:999;position:relative;max-width:100%;margin:10px 0;}body{-webkit-touch-callout:none;font family:-apple-system-font,BlinkMacSystemFont,"Helvetica Neue","PingFang SC","Hiragino Sans GB","Microsoft YaHei UI","Microsoft YaHei",Arial,sans-serif;color:#333;letter-spacing:.034em}h1,h2,h3,h4,h5,h6{font-weight:400;font-size:16px;line-height:36px;}a{color:#576b95;text-decoration:none;-webkit-tap-highlight-color:rgba(0,0,0,0)}td,th{word-wrap:break-word;padding:5px 10px;border:1px solid #DDD;}table{margin-bottom:10px;border-collapse:collapse;display:table;width:100%!important;}.appmsg_skin_default .rich_media_area_primary{background-color:#fff}.appmsg_skin_default .rich_media_area_primary .weui-loadmore_line .weui-loadmore__tips{background-color:#fff}.rich_media_area_primary{padding:20px 16px 12px;background-color:#fafafa}@media (max-width:375px){.rich_media_area_primary{padding:20px 60px 15px 60px}.rich_media_area_extra{padding:0 60px 21px 60px}}@media (min-width:1024px){.rich_media_area_primary_inner,.rich_media_area_extra_inner,body{max-width:677px;margin-left:auto;margin-right:auto}.rich_media_area_primary{padding-top:32px}}.rich_media{padding:20px;}.appmsg_skin_default .rich_media_area_primary{background-color:#fff}.appmsg_skin_default .rich_media_area_primary .weui-loadmore_line .weui-loadmore__tips{background-color:#fff}@media screen and (min-width:1024px){.rich_media_area_primary_inner,.rich_media_area_extra_inner{max-width:677px;margin-left:auto;margin-right:auto}.rich_media_area_primary{padding-top:32px}}.rich_media_content{overflow:hidden;color:#333;font-size:17px;line-height:37px;;word-wrap:break-word;-webkit-hyphens:auto;-ms-hyphens:auto;hyphens:auto;text-align:justify;position:relative;z-index:0}.rich_media_content *{max-width:100%!important;box-sizing:border-box!important;-webkit-box-sizing:border-box!important;word-wrap:break-word!important}.rich_media_content p{clear:both;min-height:1em}.rich_media_content em{font-style:italic}.rich_media_content fieldset{min-width:0}.rich_media_content .list-paddingleft-1,.rich_media_content .list-paddingleft-2,.rich_media_content .list-paddingleft-3{padding-left:2.2em}.rich_media_content .list-paddingleft-1 .list-paddingleft-2,.rich_media_content .list-paddingleft-2 .list-paddingleft-2,.rich_media_content .list-paddingleft-3 .list-paddingleft-2{padding-left:30px}.rich_media_content .list-paddingleft-1{padding-left:1.2em}.rich_media_content .list-paddingleft-3{padding-left:3.2em}.rich_media_content .code-snippet,.rich_media_content .code-snippet__fix{max-width:1000%!important}.rich_media_content .code-snippet *,.rich_media_content .code-snippet__fix *{max-width:1000%!important}.rich_media_title{font-size:22px;line-height:42px;;line-height:1.4;margin:10px 0;padding-bottom:10px;border-bottom:1px solid #e7e7eb;}@supports(-webkit-overflow-scrolling:touch){.rich_media_title{font-weight:700}}.rich_media_meta{display:inline-block;vertical-align:middle;margin:0 10px 10px 0;font-size:15px;line-height:35px;;line-height:35px;;line-height:35px;;line-height:35px;;-webkit-tap-highlight-color:rgba(0,0,0,0)}.rich_media_meta.icon_appmsg_tag{margin-right:4px}.rich_media_meta.meta_tag_text{margin-right:0}.rich_media_meta_list em{font-style:normal}.rich_media_meta_text{color:rgba(0,0,0,0.3)}p{margin:0;}.msgBox{margin-top:20px;padding-top:20px;padding-left:50px;overflow:hidden;border-top:2px dashed #09a2ff;}.msg{padding-top:7px;clear:both;}.msgBody{float:right;width:100%;margin-left:55px;padding-bottom:15px;border-bottom:1px dashed #e0e0e0;}.userHeadImg{float:left;margin-left:-50px;}.userHeadImg img{width:40px;height:40px;margin-right:10px;border-radius:3px;}.userName{color:#888888;line-height:24px;font-size:14px;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;line-height:34px;;margin:5px 0 5px 0;height:24px;}.replyBody,.autherBody{color:#565656;font-size:15px;}.replyIcon{border-left:4px solid #33ab01;margin-right:5px;}.ad{text-decoration:none;color:#d6d4d4;font-size:12px;line-height:32px;;}.msgBodyReply{padding-top:5px;}.userName span{float:right;color:#afafaf;font-size:14px;}code{text-align:left;font-size:14px;display:block;white-space:pre;display:-webkit-box;display:-webkit-flex;display:flex;position:relative;}.code-snippet__fix{font-size:14px;margin:10px 0;display:block;color:#333;position:relative;background-color:rgba(0,0,0,0.03);border:1px solid #f0f0f0;border-radius:2px;display:-webkit-box;display:-webkit-flex;display:flex;padding-left:25px;line-height:26px}.code-snippet__fix code{text-align:left;font-size:14px;display:block;white-space:pre;display:-webkit-box;display:-webkit-flex;display:flex;position:relative;font family:Consolas,"Liberation Mono",Menlo,Courier,monospace}.code-snippet__comment,.code-snippet__quote{color:#afafaf;font-style:italic}.code-snippet__keyword,.code-snippet__selector-tag,.code-snippet__subst{color:#ca7d37}.code-snippet__number,.code-snippet__literal,.code-snippet__variable,.code-snippet__template-variable,.code-snippet__tag .code-snippet__attr{color:#0e9ce5}.code-snippet__string,.code-snippet__doctag{color:#d14}.code-snippet__title,.code-snippet__section,.code-snippet__selector-id{color:#d14}.code-snippet__subst{font-weight:normal}.code-snippet__type,.code-snippet__class .code-snippet__title{color:#0e9ce5}.code-snippet__tag,.code-snippet__name,.code-snippet__attribute{color:#0e9ce5;font-weight:normal}.code-snippet__regexp,.code-snippet__link{color:#ca7d37}.code-snippet__symbol,.code-snippet__bullet{color:#d14}.code-snippet__built_in,.code-snippet__builtin-name{color:#ca7d37}.code-snippet__meta{color:#afafaf}.code-snippet__deletion{background:#fdd}.code-snippet__addition{background:#dfd}.code-snippet__emphasis{font-style:italic}.code-snippet__strong{font-weight:bold}.account_avatar{width:40px;height:40px;padding:0;}.account_info{display:-webkit-box;display:-webkit-flex;display:flex;-webkit-box-align:center;-webkit-align-items:center;padding:20px 0;align-items:center}.flex_bd{padding-left:14px;}.account_nickname{display:inline-block;vertical-align:middle;line-height:1.2;color:#576b95;font-size:14px}.account_desc{overflow:hidden;text-overflow:ellipsis;display:-webkit-box;-webkit-box-orient:vertical;-webkit-line-clamp:1;color:rgba(0,0,0,0.3);font-size:14px;line-height:1.2;padding-top:.4em}.msg_source_url{text-align:left;word-break:break-all;margin-top:20px;}.msg_source_url a{padding-right:10px;}.msg_source_url .url_text{color:#a8a8a8;}.video-desc{font-size:14px;margin-top:15px;color:#6c6c6c;}.msg_source_url{text-align:left;}.original_primary_card_tips{color:rgba(0,0,0,0.3);line-height:1.4;font-size:15px;}.weui-flex__item{margin-bottom:20px;padding:20px 16px;margin-top:16px;line-height:1.4;align-items:center;background-color:#f7f7f7;border-radius:8px;position:relative;}.original_primary_desc{color:rgba(0,0,0,0.5);font-size:14px;padding-top:4px;width:auto;overflow:hidden;text-overflow:ellipsis;}.msgBodyReplyList{border-top:1px solid #e1e1e1;margin-top:10px;}.msgBodyReplyListTop{border-top:0;}.reply_like_num{float:right;font-size:14px;color:#c7c7c7;}.msgData{margin-top:20px;color:#626262;}.msgData span{font-size:14px;padding-right:15px;}.msgData .likes{float:right;padding-right:0;}.js_text_content p{font-size:18px;line-height:38px;;}.rich_media_meta_link{font-size:15px;}blockquote {padding-left: 10px;border-left: 3px solid #dbdbdb;color: rgba(0,0,0,0.5);font-size:15px;line-height:35px;;padding-top: 4px;margin: 1em 0;}.video_iframe{width:500px;height:400px;}.blockquote_info{color:#b5b5b5;margin-top:10px;}.playVideoWx{position:relative;display:block;}.icon_mid_play{position:absolute;z-index:9999;top:50%;left:50%;display:-webkit-box;display:-webkit-flex;display:flex;-webkit-box-align:center;-webkit-align-items:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;justify-content:center;width:48px;height:48px;background:rgba(237,237,237,0.9);border-radius:50%}.icon_mid_play:before{content:"";text-indent:-999em;display:inline-block;width:28px;height:28px;vertical-align:middle;background-size:cover;background-image:url("data:image/svg+xml;charset=utf8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='24' height='24' viewBox='0 0 24 24'%3E  %3Cpath fill='%23151515' fill-rule='evenodd' d='M9.524 4.938l10.092 6.21a1 1 0 0 1 0 1.704l-10.092 6.21A1 1 0 0 1 8 18.21V5.79a1 1 0 0 1 1.524-.852z'/%3E%3C/svg%3E")}
</style>
<link href="https://www.juyifx.cn/config/css/wxArticle.css" rel="stylesheet"/>
</head>
<body>
<div class="rich_media">
                
                <h2 class="rich_media_title" id="activity-name"><a href="http://mp.weixin.qq.com/s?__biz=MzU1NDU4MTU5MQ==&mid=2247484708&idx=2&sn=d6dca9a2cebd92dd15ded00069d45f36&chksm=fbe02e1ccc97a70a59b5725c193e1acfaf880e40d59a1c869d706c07b0ac4fb513af96b7622f#rd" title="点击文章标题可访问原文章链接" target="_blank">
                    
                    
                    
转需！园区企业提供晚期或复发性非小细胞肺癌患者的免费治疗机会
                </a></h2>
                <div id="meta_content" class="rich_media_meta_list">
                                                                                
                                        <span class="rich_media_meta rich_media_meta_nickname" id="profileBt">
                      <a href="javascript:void(0);" id="js_name">
                        金鸡湖先锋                      </a>
                      <div id="js_profile_qrcode" class="profile_container" style="display:none;">
                          <div class="profile_inner">
                              <strong class="profile_nickname">金鸡湖先锋</strong>
                              <img class="profile_avatar" id="js_profile_qrcode_img" >

                              <p class="profile_meta">
                              <label class="profile_meta_label">微信号</label>
                              <span class="profile_meta_value">gh_e5d440294464</span>
                              </p>

                              <p class="profile_meta">
                              <label class="profile_meta_label">功能介绍</label>
                              <span class="profile_meta_value">全面展示苏州工业园区党工委组织部党建、干部、人才等工作成果。</span>
                              </p>
                              
                          </div>
                          <span class="profile_arrow_wrp" id="js_profile_arrow_wrp">
                              <i class="profile_arrow arrow_out"></i>
                              <i class="profile_arrow arrow_in"></i>
                          </span>
                      </div>
                    </span>
                    <em id="publish_time" class="rich_media_meta rich_media_meta_text">2018-02-27</em>
                </div>

                
                                                <div id="js_tags" class="article-tag__list" style="display: none;" data-len="0">
                                            
                        <div class="article-tag-card__title">收录于话题</div>
                        <div class="article-tags">
                                                    </div>
                                    </div><div id="weixin_content"><section data-role="outer" label="Powered by 135editor.com" style="font-size:16px;line-height:36px;;"><p style=""><img class="" data-copyright="0" data-ratio="0.15625" src="https://mmbiz.qpic.cn/mmbiz_gif/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansok1EeC9eJWM2S7g2lZDVcb1e8TiaqQ2hXoEicyzV2qAeyvrsftuTDBpTw/640?wx_fmt=gif" data-type="gif" data-w="640"></p><section class="_135editor" style=""><section class=""><section class="" style="color: rgb(23, 20, 20);"><section class="_135editor" data-tools="135编辑器" data-id="85375" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;" data-color="rgb(55, 74, 174)" data-custom="rgb(55, 74, 174)"><section style="border-width: 1px;border-style: solid;border-color: rgb(55, 74, 174);margin-top: 0.5em;box-sizing: border-box;"><section style="margin-bottom: 0.3em;"><section style="font-size: 1em;font-weight: bold;text-align: center;text-decoration: inherit;color: rgb(254, 254, 254);border-color: rgb(55, 74, 174);width: 100%;box-sizing: border-box;" data-width="100%"><section class="135brush" data-brushtype="text" style="padding: 0.6em;line-height: 1.2em;font-size: 1.2em;color: inherit;border-color: rgb(55, 74, 174);background-color: rgb(55, 74, 174);box-sizing: border-box;"><p style="font-size: medium;"><strong>晚期或复发性非小细胞肺癌患者的</strong></p><p style="font-size: medium;"><strong>免费治疗机会</strong></p></section><section style="width: 0px;margin-right: auto;margin-left: auto;border-top: 0.8em solid rgb(55, 74, 174);border-bottom-color: rgb(55, 74, 174);height: 10px;color: inherit;border-left: 0.8em solid transparent !important;border-right: 0.8em solid transparent !important;box-sizing: border-box;"></section></section></section><section style="margin: 10px;font-weight: bold;text-align: center;text-decoration: inherit;box-sizing: border-box;color: inherit;"><section style="padding: 0.5em;line-height: 1.2em;font-size: 1em;box-sizing: border-box;background-color: rgb(254, 254, 254);color: inherit;"><p style="color: inherit;line-height: 2em;"><br  /></p><section data-style="text-align: justify; line-height: 1.75em; color: rgb(127,127,127);" style="margin:5px;"><p style="text-align: left;line-height: 2em;color: inherit;"><span style="border-color: #374AAE;color: #374AAE;"></span><span style="font-size:14px;line-height:34px;;letter-spacing: 2px;text-align: justify;white-space: pre-wrap;color: rgb(38, 38, 38);">近日，由信达生物制药（苏州）有限公司发起的“在晚期或复发性非鳞状细胞非小细胞肺癌初治受试者中比较IBI305联合紫杉醇/卡铂与贝伐珠单抗联合紫杉醇/卡铂治疗有效性和安全性的随机、双盲、多中心III期研究”已获得CFDA批准（批件号：2016L04809），现正在进行患者招募，期望能为更多的一线治疗患者带来最大的获益。</span><span style="color:#7F7F7F;"></span></p></section></section></section></section></section><p style="text-align: justify;"><br  /></p></section></section></section><section class="_135editor" style="" data-color="rgb(55, 74, 174)" data-custom="rgb(55, 74, 174)"><section class="" style="margin-top: 0.5em;margin-bottom: 0.5em;"><section class="" style="padding-top: 3px;border-top: 2px solid rgb(55, 74, 174);border-right-color: rgb(55, 74, 174);border-bottom-color: rgb(55, 74, 174);border-left-color: rgb(55, 74, 174);box-sizing: border-box;"><section class="" style="padding-right: 0.5em;padding-left: 0.5em;display: inline-block;vertical-align: top;height: 2em;line-height: 2em;background-color: rgb(55, 74, 174);color: rgb(255, 255, 255);box-sizing: border-box;"><p>参与该实验的主要条件如下：</p></section><section style="width: 0px;display: inline-block;vertical-align: top;border-left: 0.8em solid rgb(55, 74, 174);border-top: 1em solid rgb(55, 74, 174);border-right: 0.8em solid transparent !important;border-bottom: 1em solid transparent !important;box-sizing: border-box;"></section></section></section></section><section class="_135editor" style=""><section class=""><section class=""><p style="letter-spacing: 2px;line-height: 2em;"><span style="letter-spacing: 0px;font-size:14px;line-height:34px;;">1. &nbsp;年龄≥18岁且≤75岁的男性或女性；</span></p><p style="letter-spacing: 2px;line-height: 2em;"><span style="font-size:14px;line-height:34px;;">2.不能手术治疗的局部晚期、转移性或复发性的非小细胞肺癌；</span></p><p style="letter-spacing: 2px;line-height: 2em;"><span style="font-size:14px;line-height:34px;;">3.未接受过对于当前疾病的化疗；</span></p><p><br  /></p><p><span style="font-size:15px;line-height:35px;;"><strong><span style="color: #202F6C;">如果您有兴趣了解关于本研究或研究药物的详情，可咨询本项目工作人员。符合条件并自愿参加该试验，您将可获得与试验相关的：1)由申办方提供的免费的药物（包括化疗药物）；2)由申办方提供的免费的检查（包括心电图、血常规、尿常规、肝肾功能、凝血功能、血/尿妊娠测定、CT扫描等）；3)由申办方提供的适当的交通补助</span></strong></span></p><p><br  /></p><p><span style="color: #202F6C;"><strong><span style="font-size:15px;line-height:35px;;">联系方式：155-2111-8409</span></strong></span></p><p><br  /></p></section></section></section><section class="_135editor" style=""><section class=""><section class="" style="text-align: center;"><p><strong>参研中心及专家名单<br  /></strong></p></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 10px;margin-bottom: 10px;text-align: center;"><section class="" style="max-width: 100%;vertical-align: middle;display: inline-block;overflow: hidden !important;"><img data-ratio="2.209375" src="https://mmbiz.qpic.cn/mmbiz_jpg/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansoheNugibHJDIv3eA0rh6ibjUJt2vBObIntPQ2licSY76a0qtqU2X7V6y5A/640?wx_fmt=jpeg" data-type="jpeg" data-w="640" style="vertical-align: middle;"></section></section></section><p style=""><br  /></p><p style="text-align: center;letter-spacing: 2px;line-height: 2em;"><span style="font-size:15px;line-height:35px;;">近年来</span></p><p style="text-align: center;letter-spacing: 2px;line-height: 2em;"><span style="font-size:15px;line-height:35px;;">单克隆抗体药物的出现</span></p><p style="text-align: center;letter-spacing: 2px;line-height: 2em;"><span style="font-size:15px;line-height:35px;;">开创了肺癌治疗的新时代</span></p><p style="text-align: center;letter-spacing: 2px;line-height: 2em;"><span style="font-size:15px;line-height:35px;;">其中贝伐珠单抗成为了</span></p><p style="text-align: center;letter-spacing: 2px;line-height: 2em;"><span style="font-size:15px;line-height:35px;;">治疗非小细胞肺癌的代表药物之一</span></p><p style="text-align: center;letter-spacing: 2px;line-height: 2em;"><span style="font-size:15px;line-height:35px;;">那么贝伐珠单抗是如何控制肿瘤的呢？</span></p><p style=""><br  /></p><p style="text-align: center;"><span style="font-size:15px;line-height:35px;;"><img data-ratio="0.91" src="https://mmbiz.qpic.cn/mmbiz_jpg/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansoCcjt9rTz4jlU9McUjGvjvxQBaSaNtibQZBHjcBq4Kicn5nDlMFuWia1aQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="400" style="vertical-align: middle;width: 269px;" width="100%"></span></p><section class="_135editor" style=""><section class="" style="margin-top: 10px;margin-bottom: 10px;"><section class="" style="padding-right: 5px;padding-left: 5px;display: inline-block;vertical-align: middle;width: 279px;box-sizing: border-box;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class=""><section class="" style="max-width: 100%;vertical-align: middle;display: inline-block;width: 269px;overflow: hidden !important;"></section></section></section></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 20px;margin-bottom: 20px;"><section class="" style="display: inline-block;width: 100%;vertical-align: top;background-color: rgb(226, 240, 251);"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: center;"><section class="" style="display: inline-block;vertical-align: middle;width: 21.9031%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="margin-top: -10px;margin-bottom: -10px;"><section class="" style="padding: 4px;display: inline-block;border-radius: 100%;background-color: rgb(95, 156, 239);box-sizing: border-box;"><section class="" style="border-radius: 100%;border-color: white;width: 1.6em;height: 1.6em;border-style: dotted;border-width: 2px;font-size:24px;line-height:44px;;line-height: 1.5em;color: rgb(255, 255, 255);box-sizing: border-box;"><p>01</p></section></section></section></section></section><section class="" style="padding-right: 5px;display: inline-block;vertical-align: middle;width: 78.0969%;box-sizing: border-box;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: left;"><section class="" style="color: rgb(62, 62, 62);letter-spacing: 0px;line-height: 1.8;"><p><strong>肺癌的发病率及治疗</strong></p></section></section></section></section></section></section></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 5px;margin-bottom: 5px;"><section class="" style="padding-right: 5px;padding-left: 5px;text-align: justify;line-height: 1.8;box-sizing: border-box;"><p style="line-height: 2em;letter-spacing: 2px;"><span style="font-size:14px;line-height:34px;;">在全球范围内，肺癌是发病率和死亡率最高的癌种。2012年全球肺癌新诊断病例约为180万例，约占全部新诊断癌症病例的13%，其中一半以上发生在欠发达地区。在我国，肺癌每年新发病例约65万，导致死亡病例约52万，占恶性肿瘤第一位。80%的肺癌为非小细胞肺癌（NSCLC），肺癌早期时通常选择解剖性肺切除术将整个肿瘤切除进行治疗，而NSCLC通常在被发现时已进入到晚期阶段，此时肿瘤已出现转移，手术无法将所有转移的肿瘤清除，所以多采用以全身治疗为主的综合？治疗最大程度地延长患者生存时间、控制疾病进展并提高生活质量。这类不可手术的晚期NSCLC治疗从上世纪80年代采取放疗和化疗联合治疗，到21世纪使用同步放化疗进行治疗，再到如今采用靶向药物联合化疗治疗，在很大程度上提升了患者生存率。</span></p></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 20px;margin-bottom: 20px;"><section class="" style="display: inline-block;width: 100%;vertical-align: top;background-color: rgb(226, 240, 251);"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: center;"><section class="" style="display: inline-block;vertical-align: middle;width: 21.9031%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="margin-top: -10px;margin-bottom: -10px;"><section class="" style="padding: 4px;display: inline-block;border-radius: 100%;background-color: rgb(95, 156, 239);box-sizing: border-box;"><section class="" style="border-radius: 100%;border-color: white;width: 1.6em;height: 1.6em;border-style: dotted;border-width: 2px;font-size:24px;line-height:44px;;line-height: 1.5em;color: rgb(255, 255, 255);box-sizing: border-box;"><p>02</p></section></section></section></section></section><section class="" style="padding-right: 5px;display: inline-block;vertical-align: middle;width: 78.0969%;box-sizing: border-box;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: left;"><section class="" style="color: rgb(62, 62, 62);letter-spacing: 0px;line-height: 1.8;"><p><strong>什么是靶向药物？</strong></p></section></section></section></section></section></section></section></section></section><section class="_135editor" style=""><section class=""><section class="" style="text-align: justify;line-height: 2;"><p style="letter-spacing: 2px;line-height: 2em;"><span style="font-size:14px;line-height:34px;;">靶向药物是指被赋予了靶向能力的药物或其制剂。打个比方，放疗或者化疗如同霰弹枪，对着林子（身体）里开一枪（进行治疗），无论好鸟（正常组织细胞）还是坏鸟（癌细胞）通通都会受到损伤。而靶向药物则是一把狙击枪，专挑癌细胞消灭，从而很大程度上保全了正常细胞。靶向药物的代表之一是单克隆抗体，例如贝伐珠单抗。由于单克隆抗体类药物靶向性好、不易出现耐药并且患者耐受性好等优点，如今已成为了各指南的首选药物。其中贝伐珠单抗联合化疗是美国国家综合癌症网络（NCCN）推荐的NSCLC一线化疗方案。东部肿瘤协作组织进行的临床研究也发现，贝伐珠单抗联合紫杉醇和卡铂较单纯化疗可以显著延长晚期、转移性或复发性非鳞状细胞NSCLC患者的总生存期和无进展生存期。</span></p></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 20px;margin-bottom: 20px;"><section class="" style="display: inline-block;width: 100%;vertical-align: top;background-color: rgb(226, 240, 251);"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: center;"><section class="" style="display: inline-block;vertical-align: middle;width: 21.9031%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="margin-top: -10px;margin-bottom: -10px;"><section class="" style="padding: 4px;display: inline-block;border-radius: 100%;background-color: rgb(95, 156, 239);box-sizing: border-box;"><section class="" style="border-radius: 100%;border-color: white;width: 1.6em;height: 1.6em;border-style: dotted;border-width: 2px;font-size:24px;line-height:44px;;line-height: 1.5em;color: rgb(255, 255, 255);box-sizing: border-box;"><p>03</p></section></section></section></section></section><section class="" style="padding-right: 5px;display: inline-block;vertical-align: middle;width: 78.0969%;box-sizing: border-box;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: left;"><section class="" style="color: rgb(62, 62, 62);letter-spacing: 0px;line-height: 1.8;"><p><strong>贝伐珠单抗的靶点-VEGF</strong></p></section></section></section></section></section></section></section></section></section><section class="_135editor" style=""><section class="" style="transform: translate3d(0px, 0px, 0px);-webkit-transform: translate3d(0px, 0px, 0px);-moz-transform: translate3d(0px, 0px, 0px);-ms-transform: translate3d(0px, 0px, 0px);-o-transform: translate3d(0px, 0px, 0px);"><section class="" style="text-align: justify;color: rgb(82, 63, 63);line-height: 2;"><p style="letter-spacing: 2px;line-height: 2em;"><span style="font-size:14px;line-height:34px;;">血管内皮生长因子(vascular endothelial growth factor， VEGF)，又称血管通透因子（vascular permeability factor, VPF），是一种细胞产出的蛋白信号。这种蛋白质信号用于刺激血管生成。正常情况下，VEGF的功能是在胚胎发育过程中刺激新的血管生成。然而在肿瘤组织中，VEGF能刺激肿瘤血管生成，使得血液中的养分通过血管源源不断地为肿瘤组织提供能量，而肿瘤细胞也能够通过血管释放各种激素诱导传播。贝伐珠单抗可以选择性地与人VEGF结合并阻断其生物活性，可抑制VEGF与其位于内皮细胞上的受体结合。通过使VEGF失去生物活性，减少肿瘤的血管形成，从而抑制了肿瘤的生长。</span></p><p style="letter-spacing: 2px;line-height: 2em;"><span style="font-size:14px;line-height:34px;;"><br  /></span></p></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 10px;margin-bottom: 10px;text-align: center;"><section class="" style="max-width: 100%;vertical-align: middle;display: inline-block;overflow: hidden !important;"><img data-ratio="0.746875" src="https://mmbiz.qpic.cn/mmbiz_jpg/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansoX02c5SWBXtDJEjw1BQ1peG3ZzYc2MgaaxpBM4uIQYhTCSP2AWx9Ajg/640?wx_fmt=jpeg" data-type="jpeg" data-w="640" style="vertical-align: middle;"></section></section><section class="" style="margin-top: 10px;margin-bottom: 10px;text-align: center;"><section class="" style="max-width: 100%;vertical-align: middle;display: inline-block;overflow: hidden !important;"><br  /></section></section></section><section class="_135editor" style=""><section class="" style="margin-top: 10px;margin-bottom: 10px;"><section class="" style="display: inline-block;vertical-align: middle;width: 9.90991%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: center;"><section class="" style="max-width: 100%;vertical-align: middle;display: inline-block;width: 44.625px;overflow: hidden !important;"><img data-ratio="1" src="https://mmbiz.qpic.cn/mmbiz_gif/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansomiaRPO9ibxJkDmYOqqOCjqzd6wT4G04XX0PQicj7ibLibNbPgb9rqHPHfiaQ/640?wx_fmt=gif" data-type="gif" data-w="260" style="vertical-align: middle;width: 44.625px;" width="100%"></section></section></section></section><section class="" style="display: inline-block;vertical-align: middle;width: 30.0901%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="margin-top: 0.5em;margin-bottom: 0.5em;"><section class="" style="border-top: 1px dashed rgb(249, 110, 87);box-sizing: border-box;"></section></section></section></section><section class="" style="display: inline-block;vertical-align: middle;width: 20%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class=""><section class="" style="text-align: center;color: rgb(249, 110, 87);"><p><strong>关于信达</strong></p></section></section></section></section><section class="" style="display: inline-block;vertical-align: middle;width: 30.0901%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="margin-top: 0.5em;margin-bottom: 0.5em;"><section class="" style="border-top: 1px dashed rgb(249, 110, 87);box-sizing: border-box;"></section></section></section></section><section class="" style="display: inline-block;vertical-align: middle;width: 9.90991%;"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class="" style="text-align: center;"><section class="" style="display: inline-block;width: 55.7969px;vertical-align: top;background-color: rgb(24, 54, 118);"><section class="_135editor" style="border-width: 0px;border-style: none;border-color: initial;box-sizing: border-box;"><section class=""><section class="" style="max-width: 100%;vertical-align: middle;display: inline-block;overflow: hidden !important;"><img data-ratio="1" src="https://mmbiz.qpic.cn/mmbiz_png/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansoMxaFuynlCstyzNcRKAjgCRQ3RMHp8rD5atpnNFrtA6AicNSqtqCfSPw/640?wx_fmt=png" data-type="png" data-w="290" style="vertical-align: middle;"></section></section></section></section></section></section></section></section></section><section class="_135editor" style=""><section class=""><section class="" style="text-align: justify;font-size:14px;line-height:34px;;color: rgb(107, 102, 102);"><p style="letter-spacing: 2px;line-height: 2em;">信达生物制药（苏州）有限公司，由国家“千人计划”特聘专家俞德超博士于2011年在苏州工业园区创建，是目前中国生物制药领域最具影响力的“独角兽”企业之一。</p><p style="letter-spacing: 2px;"><br  /></p><p style="letter-spacing: 2px;line-height: 2em;">成立以来，信达生物始终坚持以国际最高标准推动创新。目前，信达生物组建了“近1%是国家千人计划专家”、“10%是海归专家”的中国顶尖生物药创新团队；获得美国富达、新加坡淡马锡等全球优质创投资本4.9亿美元；已建设中国规模最大、同时符合中国、美国、欧盟标准的高端生物药产业化基地；13个单克隆抗体新药品种组成的产品链中，5个品种是国家“重大新药创制”专项；2015年，信达生物与美国礼来签下了33亿美元的“中国生物制药国际合作第一单”，开创了中国生物制药企业发展的新模式。</p><p style="letter-spacing: 2px;line-height: 2em;"><br  /></p><p style="letter-spacing: 2px;line-height: 2em;"><br  /></p><p style="text-align: center;"><span style="color: rgb(136, 136, 136);font-size:12px;line-height:32px;;"><strong><span style="color: rgb(136, 136, 136);">来源：信达生物，版权归原作者所有</span></strong></span></p><p style="text-align: center;"><span style="color: rgb(136, 136, 136);font-size:12px;line-height:32px;;"><strong><span style="font-size:12px;line-height:32px;;color: rgb(136, 136, 136);">文中内容不代表本号立场，亦不承担任何责任</span></strong></span></p></section></section></section><p style=""><img class="" data-copyright="0" data-ratio="0.23706896551724138" src="https://mmbiz.qpic.cn/mmbiz_gif/dtKt6iawKSvnK39iawMhzvwx4Rr4CZansocwLcicvx8SH2URGCkYIVDibCKfnCRuL2LcldiadhVlN3ux4icic2bzSjm1w/640?wx_fmt=gif" data-type="gif" data-w="696"></p></section>
                </div>
</div>
</body>
</html>